TY - JOUR
T1 - Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6
AU - Witzens-Harig, Mathias
AU - Hose, Dirk
AU - Jünger, Simone
AU - Pfirschke, Christina
AU - Khandelwal, Nisit
AU - Umansky, Ludmila
AU - Seckinger, Anja
AU - Conrad, Heinke
AU - Brackertz, Bettina
AU - Rème, Thierry
AU - Gueckel, Brigitte
AU - Meißner, Tobias
AU - Hundemer, Michael
AU - Ho, Anthony D
AU - Rossi, Jean-Francois
AU - Neben, Kai
AU - Bernhard, Helga
AU - Goldschmidt, Hartmut
AU - Klein, Bernard
AU - Beckhove, Philipp
PY - 2013
Y1 - 2013
N2 - Although functionally competent cytotoxic, T cells are frequently observed in malignant diseases, they possess little ability to react against tumor cells. This phenomenon is particularly apparent in multiple myeloma. We here demonstrate that cytotoxic T cells reacted against myeloma antigens when presented by autologous dendritic cells, but not by myeloma cells. We further show by gene expression profiling and flow cytometry that, similar to many other malignant tumors, freshly isolated myeloma cells expressed several carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) at varying proportions. Binding and crosslinking of CEACAM-6 by cytotoxic T cells inhibited their activation and resulted in T-cell unresponsiveness. Blocking of CEACAM-6 on the surface of myeloma cells by specific monoclonal antibodies or CEACAM-6 gene knock down by short interfering RNA restored T-cell reactivity against malignant plasma cells. These findings suggest that CEACAM-6 plays an important role in the regulation of CD8+ T-cell responses against multiple myeloma; therefore, therapeutic targeting of CEACAM-6 may be a promising strategy to improve myeloma immunotherapy.
AB - Although functionally competent cytotoxic, T cells are frequently observed in malignant diseases, they possess little ability to react against tumor cells. This phenomenon is particularly apparent in multiple myeloma. We here demonstrate that cytotoxic T cells reacted against myeloma antigens when presented by autologous dendritic cells, but not by myeloma cells. We further show by gene expression profiling and flow cytometry that, similar to many other malignant tumors, freshly isolated myeloma cells expressed several carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) at varying proportions. Binding and crosslinking of CEACAM-6 by cytotoxic T cells inhibited their activation and resulted in T-cell unresponsiveness. Blocking of CEACAM-6 on the surface of myeloma cells by specific monoclonal antibodies or CEACAM-6 gene knock down by short interfering RNA restored T-cell reactivity against malignant plasma cells. These findings suggest that CEACAM-6 plays an important role in the regulation of CD8+ T-cell responses against multiple myeloma; therefore, therapeutic targeting of CEACAM-6 may be a promising strategy to improve myeloma immunotherapy.
KW - Antigens, CD/genetics
KW - CD8-Positive T-Lymphocytes/immunology
KW - Cell Adhesion Molecules/genetics
KW - Coculture Techniques
KW - Cytotoxicity, Immunologic/genetics
KW - GPI-Linked Proteins/genetics
KW - Humans
KW - Immunotherapy/methods
KW - MCF-7 Cells
KW - Multiple Myeloma/immunology
KW - Plasma Cells/immunology
KW - RNA, Small Interfering/genetics
KW - Signal Transduction/immunology
KW - T-Lymphocytes, Cytotoxic/immunology
KW - Tumor Cells, Cultured
KW - U937 Cells
U2 - 10.1182/blood-2012-05-429415
DO - 10.1182/blood-2012-05-429415
M3 - Article
C2 - 23603913
SN - 0006-4971
VL - 121
SP - 4493
EP - 4503
JO - Blood
JF - Blood
IS - 22
ER -